Lifeboat Foundation

Episode Disclaimer — The views presented in this episode are those of the speaker and do not necessarily represent the views of the United States Department of Defense (DoD) or its components.

Dr. Diane DiEuliis, Ph.D. is a Distinguished Research Fellow at National Defense University (NDU — https://www.ndu.edu/), an institution of higher education, funded by the United States Department of Defense, aimed at facilitating high-level education, training, and professional development of national security leaders. Her research areas focus on emerging biological technologies, biodefense, and preparedness for biothreats. Specific topic areas under this broad research portfolio include dual-use life sciences research, synthetic biology, the U.S. bioeconomy, disaster recovery, and behavioral, cognitive, and social science as it relates to important aspects of deterrence. Dr. DiEuliis currently has several research grants in progress, and teaches in foundational professional military education.

Continue reading “Dr. Diane DiEuliis — NDU — Preparing National Security Leaders For The Next Generation Of Threats” »

This video explores the 4th to the 10th dimensions of time. Watch this next video about the 10 stages of AI: • The 10 Stages of Artificial Intelligence.
🎁 5 Free ChatGPT Prompts To Become a Superhuman: https://bit.ly/3Oka9FM
🤖 AI for Business Leaders (Udacity Program): https://bit.ly/3Qjxkmu.
☕ My Patreon: / futurebusinesstech.
➡️ Official Discord Server: / discord.

💡 Future Business Tech explores the future of technology and the world.

Continue reading “What If We Accessed The 10th Dimension?” »

ESA’s newly graduated astronauts reach the end of one year of rigorous basic astronaut training. Discover the journey of Sophie Adenot, Rosemary Coogan, Pablo Álvarez Fernández, Raphaël Liégeois, Marco Sieber, and Australian Space Agency astronaut candidate Katherine Bennell-Pegg. Selected in November 2022, the group began their training in April 2023.

Basic astronaut training provides the candidates with an overall familiarisation and training in various areas, such as spacecraft systems, spacewalks, flight engineering, robotics and life support systems as well as survival and medical training. They received astronaut certification at ESA’s European Astronaut Centre on 22 April 2024.

Continue reading “A year in training: ESA’s new astronauts graduate” »

Researchers at the Francis Crick Institute, the National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH) and Aalborg University in Denmark have found that vitamin D encourages the growth of a type of gut bacteria in mice which improves immunity to cancer.

Reported today in Science, the researchers found that mice given a diet rich in vitamin D had better immune resistance to experimentally transplanted cancers and improved responses to immunotherapy treatment. This effect was also seen when gene editing was used to remove a protein that binds to vitamin D in the blood and keeps it away from tissues.

Surprisingly, the team found that vitamin D acts on epithelial cells in the intestine, which in turn increase the amount of a bacteria called Bacteroides fragilis. This microbe gave mice better immunity to cancer as the transplanted tumours didn’t grow as much, but the researchers are not yet sure how.

Structural and dynamic DNA nanosciences offer unique tools for engineering bottom–up synthetic cells. This Review provides a holistic overview for using DNA as a structural material, for designing functional entities, and for information-processing circuits for adaptive and interactive behaviour.

A trailblazer in the field of therapeutic genome editing, Fyodor D. Urnov’s research focuses on developing medicines for devastating genetic diseases.

Jason Comander, MD, PhD, performs the procedure to deliver the CRISPR-based medicine as part of the BRILLIANCE trial in September 2020 at Mass Eye and Ear. Credit: Mass Eye and Ear.

All 14 trial participants, including 12 adults (ages 17 to 63) and two children (ages 10 and 14), were born with a form of Leber Congenital Amaurosis (LCA) caused by mutations in the centrosomal protein 290 (CEP290) gene. They underwent a single injection of a CRISPR/Cas9 genome editing medicine, EDIT-101 in one eye via a specialized surgical procedure. This trial, which included the first patient to ever receive a CRISPR-based investigational medicine directly inside the body, focused primarily on safety with a secondary analysis for efficacy.

No serious treatment or procedure-related adverse events were reported, nor were there any dose-limiting toxicities. For efficacy, the researchers looked at four measures: best-corrected visual acuity (BCVA); dark-adapted full-field stimulus testing (FST), visual function navigation (VNC, as measured by a maze participants completed), and vision-related quality of life.

A simple and robust strategy developed by KAUST scientists could help to improve the safety and accuracy of CRISPR gene editing, a tool that is already approved for clinical use for the treatment of inherited blood disorders.

Following the landmark approval of the first CRISPR-based cell therapy in December 2023, the CRISPR community is looking ahead to the next wave of commercial successes, fueled by continued innovation in the development of new gene editing and delivery tools and technologies. Equally exciting advances are occurring in livestock editing, xenotransplantation, and many other specialties.

In The State of CRISPR and Gene Editing virtual summit, GEN proudly gathers a tantalizing line-up of luminaries from academia and industry to discuss the latest research developments, innovations, and advanced technologies that are expanding the CRISPR toolbox, delivering new therapies to patients and safeguarding our food supply.